Fast-track: Short Interval in Treatment of PJI

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Unknown status
CT.gov ID
NCT02372435
Collaborator
(none)
418
2
36

Study Details

Study Description

Brief Summary

Patients with hip, knee and shoulder PJI, will be treated with a two-stage exchange Revision.

Patients will be randomized into 2 groups: the experimental Group will get a reimplantation after a short interval (2-3 weeks) while the control Group after a long standard interval.

Primary objective of the study is "Infection outcome". The infection-free status is defined as absence of clinical (e.g. no fistula), laboratory (e.g. normal C-reactive protein) and radiological signs of infection (e.g. no septic loosening).

Secondary objective is "Functional outcome".The functional assessment will be performed using joint-specific scores (HARRIS HIP SCORE, CONSTANT SHOULDER SCORE, KNEE SOCIETY SCORE, OXFORD HIP SCORE, OXFORD KNEE SCORE, QUICK DASH SCORE) involving the range of motion (ROM), patient mobility / independency in daily life, subjective evaluation of pain using a visual analog pain scale (1-10 points) and life-quality evaluation (EQ5D5L score).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Shortening of the interval of two-stage prosthesis exchange
N/A

Detailed Description

A two-stage prosthesis exchange after a long interval of ≥6 weeks is considered the "gold standard" for management of prosthetic joint infection (PJI). We will compare the efficacy and safety of a novel surgical approach with short interval of 2-3 weeks ("fast-track") compared to the standard long interval of 6-10 weeks. Included will be patients with hip, knee or shoulder PJI, in whom all prosthetic components are removed; excluded will be patients treated with prosthesis retention or one-stage exchange and PJI caused by difficult-to-treat organisms. Patients will be randomized into short versus long interval surgical procedure, using a standard antibiotic regimen of 12 weeks in both study arms. The recruitment period of this multicenter treatment/outcome trial is 24 months, follow-up period 12 months and the calculated sample size 418 patients (i.e. 209 patient for each study arm). Primary endpoint is the infection outcome, secondary endpoint is the functional outcome, defined by established scores for joint-specific scores, pain and quality of life scores. The expected outcomes in the short interval ("fast-track") arm are (i) improved infection outcome (i.e. longer infection-free period and less treatment-related adverse events); (ii) improved functional outcome, and (iii) reduced healthcare expenses. In addition, pharmacokinetic studies will be performed and a biobank of microbes and biological samples will be established. This study has high clinical relevance for an increasing public health challenge related to device-associated infections.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
418 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of Fast-track Treatment for Prosthetic Joint Infection (PJI)
Study Start Date :
May 1, 2015
Anticipated Primary Completion Date :
May 1, 2017
Anticipated Study Completion Date :
May 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Short interval

Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation ("fast-track-arm").

Procedure: Shortening of the interval of two-stage prosthesis exchange
The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.

Active Comparator: Long interval

Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).

Procedure: Shortening of the interval of two-stage prosthesis exchange
The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.

Outcome Measures

Primary Outcome Measures

  1. Infection outcome [12 months after surgery]

    Duration of infection-free interval and frequency of adverse events related to surgical treatment. The infection-free status is defined as absence of clinical (e.g. no fistula), laboratory (e.g. normal C-reactive protein) and radiological signs of infection (e.g. no septic loosening).

Secondary Outcome Measures

  1. Functional outcome [12 months after surgery]

    The functional assessment will be performed using joint-specific scores (HARRIS HIP SCORE, CONSTANT SHOULDER SCORE, KNEE SOCIETY SCORE, OXFORD HIP SCORE, OXFORD KNEE SCORE, QUICK DASH SCORE) involving the range of motion (ROM), patient mobility / independency in daily life, subjective evaluation of pain using a visual analog pain scale (1-10 points) and life-quality evaluation (EQ5D5L score).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects aged ≥18 years with hip, knee or shoulder PJI, in whom all prosthetic components are removed.

  • The standard treatment for systemic and local antibiotics is followed (predetermined algorithm).

  • Subjects are willing to participate in the study (signed informed consent) and comply with planned follow-up assessments (at 3, 6 and 12 months after study inclusion).

Exclusion Criteria:
  • Treatment with debridement and prosthesis retention (e.g. performed in early postoperative or acute hematogenous infections with symptom duration <3 weeks) or one-stage exchange.

  • PJI caused by difficult-to-treat organisms, including rifampin-resistant staphylococci, quinolone-resistant Gram-negative bacilli and fungi.

  • Subject previously enrolled in this study or is currently enrolled in another competitive investigational study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Charite University, Berlin, Germany

Investigators

  • Principal Investigator: Andrej Trampuz, PD, Charite University, Berlin, Germany

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrej Trampuz, PD Dr. Andrej Trampuz, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT02372435
Other Study ID Numbers:
  • ChariteU
First Posted:
Feb 26, 2015
Last Update Posted:
Feb 26, 2015
Last Verified:
Feb 1, 2015
Keywords provided by Andrej Trampuz, PD Dr. Andrej Trampuz, Charite University, Berlin, Germany
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 26, 2015